US FDA approves Biocon unit’s biosimilar to blockbuster eye drug Eylea

(Reuters) – The U.S. Food and Drug Administration on Monday approved Biocon unit’s biosimilar to Regeneron Pharmaceuticals’ blockbuster eye drug Eylea, according to information on the agency’s website.

(Reporting by Leroy Leo in Bengaluru; Editing by Shilpi Majumdar)